Empower Pharmacy's FDA Warning Letter: What It Means for GLP-1 Compounders and Aseptic Data Integrity

On 18 September 2026, the United States Food and Drug Administration issued a warning letter to Empower Clinic Services, LLC, doing business as Empower Pharmacy in Houston, Texas, one of the largest compounding pharmacies in the country. The pharmacy was cited for compounding semaglutide and tirzepatide products that FDA considers essentially copies of approved drugs, for aseptic processing failures in its sterile operations, and for data integrity gaps in its media fill records. For any company that fills sterile injectables, and especially for the wave of businesses that entered GLP-1 compounding during the shortage years, the letter is a detailed map of exactly where FDA is looking.

The timing matters. The national shortages of semaglutide and tirzepatide are over. The legal shelter that let pharmacies and outsourcing facilities compound copies of these drugs has closed. What remains is a market under close federal watch, where a single inspection can surface both a scope problem, compounding drugs you are no longer permitted to copy, and a quality problem, sterile processes that cannot prove they work. This article breaks down what the Empower Pharmacy letter says, why it happened now, and what sterile compounders and manufacturers on both sides of the border should do before their own inspection.

MFLRC works with pharmaceutical manufacturers, compounders and licence holders in Canada, the United States and Europe. The regulatory citations here are American, but the quality lessons, aseptic control, media fill design and data integrity, apply directly to Health Canada and EU-GMP expectations as well.

Executive Summary

FDA's warning letter to Empower Pharmacy, posted publicly on 22 September 2026, cites the pharmacy under section 503A of the Federal Food, Drug, and Cosmetic Act for compounding non-individualized semaglutide and tirzepatide products that are essentially copies of approved drugs, and under section 501 for insanitary conditions and current good manufacturing practice failures in its sterile operations. The specific findings, inadequate smoke studies for ISO 5 airflow, media fills that were not run under the most challenging conditions, and media fill records transcribed onto a new form with no audit trail, are among the most common and most preventable citations FDA issues to sterile facilities. Compounders that built GLP-1 lines during the shortage now face a market where the copy exemption is gone and aseptic discipline is the whole game. The practical response is a documented gap assessment against 503A scope rules and aseptic CGMP, a media fill programme redesigned around worst-case conditions, and a data integrity review of every quality record.

What the Empower Pharmacy warning letter says

In short: FDA inspected Empower Pharmacy, a state-licensed 503A compounding pharmacy in Houston, and found two categories of problem. First, a scope problem: the pharmacy was compounding semaglutide and tirzepatide products regularly and in what FDA called inordinate amounts, without the prescriber-specific determination that a compounded copy was clinically necessary. Second, a quality problem: the sterile operation could not demonstrate control of its aseptic environment, and its records did not reliably show what actually happened. FDA cited the products as adulterated under section 501 and as unapproved new drugs under section 505.

The letter gave Empower fifteen working days to respond with corrective actions and recommended the pharmacy engage a third party consultant with sterile drug manufacturing expertise. Warning letters are not the end of an enforcement path. They are a formal, public notice that FDA believes violations are serious enough to require documented correction, and that failure to correct can lead to seizure, injunction or referral. Because the letter is public, it also functions as guidance to the rest of the industry about where inspection attention is focused.

Why the shortage list is the whole story

Why it matters: compounding a copy of an approved drug is normally prohibited. During a national shortage, FDA uses enforcement discretion to let compounders fill the gap. When the shortage ends, that discretion ends, and the ordinary rule returns. The Empower findings only make sense against this backdrop. The semaglutide and tirzepatide shortages are resolved, so the copies FDA found are no longer covered by any shortage exemption.

Under section 503A of the Federal Food, Drug, and Cosmetic Act, a compounded drug that is essentially a copy of a commercially available, FDA-approved product is generally not eligible for the exemptions that let compounders operate without an approved application. There is a narrow exception when a prescriber determines that the compounded version produces a significant difference for a specific patient. FDA's concern at Empower was that this determination was missing or boilerplate: order language repeated verbatim across many records, which does not evidence a patient-specific clinical judgement.

The timeline below shows why the window closed. Once a drug leaves the shortage list, FDA sets a short grace period, then enforcement discretion ends. The dates come from FDA's own compounding policy statement.

By the time of the 2026 inspection, both drugs had been off the shortage list for more than a year. A pharmacy still compounding them at volume needed a defensible, patient-specific rationale for every unit. FDA did not find one. This is the scope trap that many GLP-1 compounders now face: the clinical demand is still there, but the legal basis that supported high-volume compounding has disappeared.

The three aseptic failures FDA cited

What to do: sterile compounding stands or falls on proof, not intention. FDA cited three failures at Empower that together mean the pharmacy could not prove its aseptic process was under control. Each is common, each is fixable, and each should be verified in your own facility now.

1. Smoke studies that do not prove unidirectional airflow

Aseptic filling relies on first-air protection: unidirectional, uninterrupted airflow over exposed sterile product and contact surfaces in the ISO 5 zone. A smoke study is the dynamic, video-recorded test that demonstrates this airflow is genuinely unidirectional during real operations, including operator interventions. FDA found Empower's smoke studies did not adequately demonstrate unidirectional airflow within the ISO 5 area. Without that proof, every claim about sterility rests on assumption.

2. Media fills not run under the most challenging conditions

A media fill, or aseptic process simulation, substitutes sterile growth medium for product and runs the full filling process to show that the process does not introduce contamination. The value of a media fill comes entirely from how realistically it stresses the process. FDA cited Empower because its media fills were not conducted under the most challenging or stressful conditions: the maximum number of interventions, personnel, shift duration, container-closure changes and other worst-case elements the process can encounter. A media fill run on an easy day proves nothing about a hard one.

We covered the design of a defensible aseptic process simulation in detail in our analysis of what FDA's 2026 media fill warning letters reveal. The Empower letter repeats the same pattern: the simulation existed, but it did not represent the real, worst-case process.

3. Aseptic conditions that were not maintained

FDA also cited a failure to establish and maintain systems to control aseptic conditions, referencing the current good manufacturing practice expectation at 21 CFR 211.42. This is the umbrella finding: when smoke studies and media fills both fall short, FDA concludes the facility cannot assure that the drugs it releases are sterile. For an injectable product, that is the highest-stakes failure a quality system can have.

When data integrity unravels the file

Why it matters: even a well-designed test is worthless if the record cannot be trusted. FDA's data integrity findings at Empower are a textbook example of how a records problem turns a quality event into a credibility crisis. When the record does not reliably show what happened, FDA cannot rely on any of the data the facility submits, including its corrective actions.

The letter describes media fill results that were transcribed onto a later revision of a form because the original results had been documented on the wrong form, with no clear audit trail linking the transcribed values back to the original observation. It also flags unexplained N/A entries on vial records, where the reader cannot tell whether a step was performed, skipped or simply not recorded. Under the ALCOA principles that underpin data integrity, records must be attributable, legible, contemporaneous, original and accurate. Transcription without an audit trail breaks original and contemporaneous at once.

This is the same failure mode we described in our guide to the investigation FDA cites first, 21 CFR 211.192. A weak record does not just fail an audit. It removes FDA's ability to believe the investigation that followed, which is why data integrity findings so often escalate.

What this means for GLP-1 and peptide compounders

What to do: treat the Empower letter as a two-part self-inspection. Part one is scope: confirm you are legally entitled to compound what you are compounding now that the shortages are over. Part two is sterility assurance: confirm you can prove your aseptic process works and that your records are trustworthy. A facility can be perfect on one and fail on the other, and FDA will cite both.

The peptide market makes this urgent. FDA has spent 2026 rejecting research use only labelling as a shield for what are, in substance, drug marketing and distribution operations. Semaglutide, tirzepatide, retatrutide and related peptides are attractive precisely because demand is high, but they are sterile injectables, which puts every unit inside the aseptic and data integrity expectations Empower failed. The commercial upside does not change the quality bar.

The finished-dose side of the same market is under equal pressure. We documented three generic semaglutide recalls in a single month and the seventeen revised FDA peptide guidances that generic developers must now work through. Compounded, generic or brand, the GLP-1 supply chain is one of the most heavily inspected in the industry right now.

Aseptic and 503A compliance checklist

Use this checklist to pressure-test your own sterile compounding operation against the Empower findings. It is not exhaustive, and it does not replace a formal gap assessment, but every item maps to a citation in the letter.

• Confirm every compounded product is either not a copy of an approved drug or is supported by a documented, prescriber-specific significant-difference determination.
• Remove boilerplate or pre-generated clinical-need language from compounding records and replace it with patient-specific rationale.
• Verify that current smoke studies demonstrate unidirectional airflow in the ISO 5 zone during dynamic operations, including interventions, and that they are video-recorded and current.
• Redesign media fills to cover worst-case conditions: maximum interventions, maximum personnel, longest shift, and all container-closure sizes and line configurations.
• Confirm media fill acceptance criteria, incubation and read procedures are defined and followed, with every unit accounted for.
• Establish and document systems that maintain aseptic conditions continuously, not only at qualification.
• Audit quality records for transcription: any value copied from one form to another must carry an audit trail linking it to the original.
• Eliminate unexplained N/A entries. Every field is either completed or carries a documented reason.
• Confirm your data integrity governance covers ALCOA principles across paper and electronic records.
• Prepare a corrective and preventive action process that can respond within the inspection response window, with root-cause analysis, not just fixes.
• Decide whether a third party sterile-manufacturing expert should review your operation before FDA requires one.

Common mistakes that turn an inspection into a warning letter

Treating the shortage exemption as permanent. Many facilities scaled GLP-1 lines in 2023 and 2024 and never revisited the legal basis when the shortages ended in 2025. Scope is now the first thing FDA checks.

Running media fills on the easiest possible day. A simulation that avoids interventions, uses minimum staff and runs a short batch produces a clean result that means nothing. FDA reads media fill design, not just the pass or fail line.

Fixing the finding but not the record. Correcting a smoke study or media fill without repairing the record system leaves the data integrity problem intact, and data integrity findings escalate fastest.

Transcribing data to tidy it up. Copying results onto a cleaner or newer form without an audit trail is one of the most common and most damaging habits in a paper-based quality system.

Waiting for the inspection to test the system. The controls FDA cited are all verifiable in-house today. A facility that self-inspects against this letter controls the outcome; one that waits does not.

Frequently asked questions

What is a 503A compounding pharmacy?

A 503A compounding pharmacy is a state-licensed pharmacy that compounds drugs for individual patients based on a valid prescription. Under section 503A of the Federal Food, Drug, and Cosmetic Act, its compounded products are exempt from certain approval, labelling and CGMP requirements, provided the pharmacy meets the conditions of the section. Compounding drugs that are essentially copies of approved products, or compounding for general distribution rather than specific patients, falls outside those conditions.

Can pharmacies still compound semaglutide or tirzepatide?

Only in narrow circumstances. Because both drugs are off the FDA shortage list, compounding a copy is no longer covered by enforcement discretion. A 503A pharmacy may compound a version only when a prescriber documents that the compounded product produces a clinically significant difference for a specific patient, for example a different dose or the removal of an ingredient the patient cannot tolerate. High-volume compounding of standard formulations is not permitted.

What is the difference between a smoke study and a media fill?

A smoke study is a visual, usually video-recorded test that demonstrates airflow in the critical ISO 5 zone is unidirectional and uninterrupted during operations. A media fill, or aseptic process simulation, replaces the drug with sterile growth medium and runs the entire filling process to show the process does not introduce contamination. The smoke study proves the environment; the media fill proves the process. FDA expects both, current and realistic.

What does ALCOA mean for data integrity?

ALCOA is the standard FDA and other regulators use to judge whether a record can be trusted. Records must be Attributable to a person, Legible and permanent, Contemporaneous with the activity, Original rather than a later copy, and Accurate. Regulators often extend it to ALCOA+, adding complete, consistent, enduring and available. The Empower letter shows what happens when contemporaneous and original break: transcribed media fill records with no audit trail.

Does an FDA warning letter affect Canadian or EU operations?

It can. FDA warning letters are public and are shared through international regulatory cooperation. Health Canada maintains a foreign action notification process, and EU-GMP inspectorates track FDA enforcement. A Canadian site that imports from, exports to or partners with a cited facility should expect questions. More broadly, the quality expectations FDA enforced here, aseptic control and data integrity, are effectively identical under Health Canada and EU-GMP, so the same findings would arise in either jurisdiction.

How quickly must a company respond to a warning letter?

The Empower letter set a fifteen working day deadline to respond with corrective actions, which is typical. A strong response includes the immediate correction, a root-cause analysis, a corrective and preventive action plan with timelines, and evidence that the fix is being verified. FDA also recommended engaging a qualified third party expert, a common step that signals the facility is taking the findings seriously.

How MFLRC can help

MFLRC is a Canadian regulatory and quality consultancy that works with pharmaceutical manufacturers, compounders and sterile operations across Canada, the United States and Europe. We help sterile facilities prepare for and respond to exactly the kind of findings the Empower letter describes.

Our support includes aseptic CGMP gap assessments and mock inspections that benchmark your operation against FDA, Health Canada and EU-GMP expectations before an inspector does; media fill and aseptic process simulation programme review, so your simulations are built around worst-case conditions and stand up to scrutiny; data integrity audits and SOP development covering ALCOA principles across paper and electronic records, aseptic processing, environmental monitoring and record control; and corrective and preventive action support, including root-cause analysis and third party review. For companies still assessing their 503A scope, we can help document a defensible position before it becomes an enforcement question.

Facing an FDA, Health Canada or EU-GMP inspection of your sterile or compounding operation? Contact MFLRC for a confidential aseptic CGMP and data integrity gap assessment before your next audit.

Conclusion

The Empower Pharmacy warning letter is not really about one company. It is a clear statement of where FDA is focused in 2026: the scope of GLP-1 compounding now that the shortages are over, and the ability of sterile facilities to prove, on paper and in practice, that their aseptic processes work. Both problems are visible from inside the facility long before an inspector arrives. Smoke studies, media fill design, aseptic control and data integrity are all testable today. The companies that treat this letter as a self-inspection checklist will be the ones who never receive their own.

Sources and references

• FDA Warning Letter to Empower Clinic Services, LLC dba Empower Pharmacy (18 September 2026)
• FDA, Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
• FDA, Human Drug Compounding: Compounding Laws and Policies (sections 503A and 503B)
• 21 CFR 211.42, Design and construction features (aseptic processing), eCFR
• MFLRC, Media Fill Failures: What FDA's 2026 Warning Letters Reveal About Aseptic Process Simulation
• MFLRC, The Investigation FDA Cites First: How to Get 21 CFR 211.192 Right
• MFLRC, Three Semaglutide Recalls in One Month: Inside the Generic GLP-1 Quality Failures